BAY 81-8973 Demonstrates Long-Term Safety and Efficacy in Children With Severe Haemophilia A: Results From the LEOPOLD Kids Extension Study

To report the long-term safety and efficacy of BAY 81-8973 in the LEOPOLD Kids extension phase. Patients received BAY 81-8973 (25-50 IU/kg) at least twice weekly. The primary endpoint was safety, assessed in all patients who entered the extension phase (n = 82). Efficacy endpoints were assessed in p...

Full description

Saved in:
Bibliographic Details
Published in:European journal of haematology 2024-12
Main Authors: Ljung, Rolf, Chan, Anthony K C, Ahuja, Sanjay P, Mancuso, Maria Elisa, Marquez, Jose Francisco Cabre, Volk, Florian, Blanchette, Victor, Kerlin, Bryce A, Trakymiene, Sonata Saulyte, Glosli, Heidi, Kenet, Gili
Format: Article
Language:English
Subjects:
Clinical Medicine
Hematologi
Hematology
Klinisk medicin
Medical and Health Sciences
Medicin och hälsovetenskap
Pediatrics
Pediatrik
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue
container_start_page
container_title European journal of haematology
container_volume
creator Ljung, Rolf
Chan, Anthony K C
Ahuja, Sanjay P
Mancuso, Maria Elisa
Marquez, Jose Francisco Cabre
Volk, Florian
Blanchette, Victor
Kerlin, Bryce A
Trakymiene, Sonata Saulyte
Glosli, Heidi
Kenet, Gili
description To report the long-term safety and efficacy of BAY 81-8973 in the LEOPOLD Kids extension phase. Patients received BAY 81-8973 (25-50 IU/kg) at least twice weekly. The primary endpoint was safety, assessed in all patients who entered the extension phase (n = 82). Efficacy endpoints were assessed in patients without high-titre inhibitors/immune tolerance induction (n = 67). Children (n = 82) received BAY 81-8973 for a median of 3.1 years per patient and a median of 405 exposure days per patient. Long-term BAY 81-8973 treatment was well tolerated, with no cases of de novo inhibitor development in the extension phase. Annualised bleeding rates (ABRs) within 48 h of prophylaxis were low for all bleeds (median [IQR], 0.7 [0-1.9]; mean, 1.4 [SD, 2.1]) and for joint bleeds (median [IQR], 0 [0-0.7]; mean, 0.5 [SD, 1.1]) (n = 67). Twenty-one of 67 patients (31.3%) had zero bleeds within 48 h of prophylaxis; the treatment response was 'good'/'excellent' in 87.9% of bleeds, and most bleeds resolved with ≤ 2 BAY 81-8973 infusions (83.5%). Long-term BAY 81-8973 treatment is well tolerated and maintains low ABRs for all bleeds and joint bleeds in children with severe haemophilia A. ClinicalTrials.gov identifier: NCT01311648.
doi_str_mv 10.1111/ejh.14362
format article
fullrecord <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_proquest_miscellaneous_3146664467</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3146664467</sourcerecordid><originalsourceid>FETCH-LOGICAL-p245t-e2bab62035d0c22f317c938df0e0878520e6e45ff3396d440f666b2548b015e83</originalsourceid><addsrcrecordid>eNpNkdtu1DAQhi0Eoge44AXQXHKT4lOcmLtlu20RkbZiixBXlpOMWVc5NXag-wy8NJZaqo40mpHm1_fPaAh5x-gZS_ERb_dnTArFX5BjpijNqKL65bP-iJyEcEsp5ZoVr8mR0EoVusiPyd_Pq59QsqzUhYBz7MchxNlGDFCNw6_sBucedtZhPIAdWtg45xvbHMAPsN77rp1xgB8-7mGHv3FGuLKJMaWJt7D6BN8wLF0McDGPPcQ9QrXZXm-rc_jq2wCb-4hD8OMAu7i0hzfklbNdwLeP9ZR8v9jcrK-yanv5Zb2qsonLPGbIa1srTkXe0oZzJ1jRaFG2jiItizLnFBXK3DmRzmylpE4pVfNcljVlOZbilFQP3PAHp6U20-x7Ox_MaL3plillndIENIWgqGtmDVVOGilaNDpHa1CLZNkIy61LuA8PuGke7xYM0fQ-NNh1dsBxCUYwmRaQUhVJ-v5RutQ9tk_O__8h_gE6CImY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3146664467</pqid></control><display><type>article</type><title>BAY 81-8973 Demonstrates Long-Term Safety and Efficacy in Children With Severe Haemophilia A: Results From the LEOPOLD Kids Extension Study</title><source>Wiley</source><creator>Ljung, Rolf ; Chan, Anthony K C ; Ahuja, Sanjay P ; Mancuso, Maria Elisa ; Marquez, Jose Francisco Cabre ; Volk, Florian ; Blanchette, Victor ; Kerlin, Bryce A ; Trakymiene, Sonata Saulyte ; Glosli, Heidi ; Kenet, Gili</creator><creatorcontrib>Ljung, Rolf ; Chan, Anthony K C ; Ahuja, Sanjay P ; Mancuso, Maria Elisa ; Marquez, Jose Francisco Cabre ; Volk, Florian ; Blanchette, Victor ; Kerlin, Bryce A ; Trakymiene, Sonata Saulyte ; Glosli, Heidi ; Kenet, Gili</creatorcontrib><description>To report the long-term safety and efficacy of BAY 81-8973 in the LEOPOLD Kids extension phase. Patients received BAY 81-8973 (25-50 IU/kg) at least twice weekly. The primary endpoint was safety, assessed in all patients who entered the extension phase (n = 82). Efficacy endpoints were assessed in patients without high-titre inhibitors/immune tolerance induction (n = 67). Children (n = 82) received BAY 81-8973 for a median of 3.1 years per patient and a median of 405 exposure days per patient. Long-term BAY 81-8973 treatment was well tolerated, with no cases of de novo inhibitor development in the extension phase. Annualised bleeding rates (ABRs) within 48 h of prophylaxis were low for all bleeds (median [IQR], 0.7 [0-1.9]; mean, 1.4 [SD, 2.1]) and for joint bleeds (median [IQR], 0 [0-0.7]; mean, 0.5 [SD, 1.1]) (n = 67). Twenty-one of 67 patients (31.3%) had zero bleeds within 48 h of prophylaxis; the treatment response was 'good'/'excellent' in 87.9% of bleeds, and most bleeds resolved with ≤ 2 BAY 81-8973 infusions (83.5%). Long-term BAY 81-8973 treatment is well tolerated and maintains low ABRs for all bleeds and joint bleeds in children with severe haemophilia A. ClinicalTrials.gov identifier: NCT01311648.</description><identifier>ISSN: 1600-0609</identifier><identifier>EISSN: 1600-0609</identifier><identifier>DOI: 10.1111/ejh.14362</identifier><identifier>PMID: 39667975</identifier><language>eng</language><publisher>England</publisher><subject>Clinical Medicine ; Hematologi ; Hematology ; Klinisk medicin ; Medical and Health Sciences ; Medicin och hälsovetenskap ; Pediatrics ; Pediatrik</subject><ispartof>European journal of haematology, 2024-12</ispartof><rights>2024 The Author(s). European Journal of Haematology published by John Wiley &amp; Sons Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0003-3999-8747</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39667975$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://lup.lub.lu.se/record/730e9b1a-06f4-43de-95ea-e93c93c3a2af$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Ljung, Rolf</creatorcontrib><creatorcontrib>Chan, Anthony K C</creatorcontrib><creatorcontrib>Ahuja, Sanjay P</creatorcontrib><creatorcontrib>Mancuso, Maria Elisa</creatorcontrib><creatorcontrib>Marquez, Jose Francisco Cabre</creatorcontrib><creatorcontrib>Volk, Florian</creatorcontrib><creatorcontrib>Blanchette, Victor</creatorcontrib><creatorcontrib>Kerlin, Bryce A</creatorcontrib><creatorcontrib>Trakymiene, Sonata Saulyte</creatorcontrib><creatorcontrib>Glosli, Heidi</creatorcontrib><creatorcontrib>Kenet, Gili</creatorcontrib><title>BAY 81-8973 Demonstrates Long-Term Safety and Efficacy in Children With Severe Haemophilia A: Results From the LEOPOLD Kids Extension Study</title><title>European journal of haematology</title><addtitle>Eur J Haematol</addtitle><description>To report the long-term safety and efficacy of BAY 81-8973 in the LEOPOLD Kids extension phase. Patients received BAY 81-8973 (25-50 IU/kg) at least twice weekly. The primary endpoint was safety, assessed in all patients who entered the extension phase (n = 82). Efficacy endpoints were assessed in patients without high-titre inhibitors/immune tolerance induction (n = 67). Children (n = 82) received BAY 81-8973 for a median of 3.1 years per patient and a median of 405 exposure days per patient. Long-term BAY 81-8973 treatment was well tolerated, with no cases of de novo inhibitor development in the extension phase. Annualised bleeding rates (ABRs) within 48 h of prophylaxis were low for all bleeds (median [IQR], 0.7 [0-1.9]; mean, 1.4 [SD, 2.1]) and for joint bleeds (median [IQR], 0 [0-0.7]; mean, 0.5 [SD, 1.1]) (n = 67). Twenty-one of 67 patients (31.3%) had zero bleeds within 48 h of prophylaxis; the treatment response was 'good'/'excellent' in 87.9% of bleeds, and most bleeds resolved with ≤ 2 BAY 81-8973 infusions (83.5%). Long-term BAY 81-8973 treatment is well tolerated and maintains low ABRs for all bleeds and joint bleeds in children with severe haemophilia A. ClinicalTrials.gov identifier: NCT01311648.</description><subject>Clinical Medicine</subject><subject>Hematologi</subject><subject>Hematology</subject><subject>Klinisk medicin</subject><subject>Medical and Health Sciences</subject><subject>Medicin och hälsovetenskap</subject><subject>Pediatrics</subject><subject>Pediatrik</subject><issn>1600-0609</issn><issn>1600-0609</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpNkdtu1DAQhi0Eoge44AXQXHKT4lOcmLtlu20RkbZiixBXlpOMWVc5NXag-wy8NJZaqo40mpHm1_fPaAh5x-gZS_ERb_dnTArFX5BjpijNqKL65bP-iJyEcEsp5ZoVr8mR0EoVusiPyd_Pq59QsqzUhYBz7MchxNlGDFCNw6_sBucedtZhPIAdWtg45xvbHMAPsN77rp1xgB8-7mGHv3FGuLKJMaWJt7D6BN8wLF0McDGPPcQ9QrXZXm-rc_jq2wCb-4hD8OMAu7i0hzfklbNdwLeP9ZR8v9jcrK-yanv5Zb2qsonLPGbIa1srTkXe0oZzJ1jRaFG2jiItizLnFBXK3DmRzmylpE4pVfNcljVlOZbilFQP3PAHp6U20-x7Ox_MaL3plillndIENIWgqGtmDVVOGilaNDpHa1CLZNkIy61LuA8PuGke7xYM0fQ-NNh1dsBxCUYwmRaQUhVJ-v5RutQ9tk_O__8h_gE6CImY</recordid><startdate>20241212</startdate><enddate>20241212</enddate><creator>Ljung, Rolf</creator><creator>Chan, Anthony K C</creator><creator>Ahuja, Sanjay P</creator><creator>Mancuso, Maria Elisa</creator><creator>Marquez, Jose Francisco Cabre</creator><creator>Volk, Florian</creator><creator>Blanchette, Victor</creator><creator>Kerlin, Bryce A</creator><creator>Trakymiene, Sonata Saulyte</creator><creator>Glosli, Heidi</creator><creator>Kenet, Gili</creator><scope>NPM</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AGCHP</scope><scope>AOWAS</scope><scope>D8T</scope><scope>D95</scope><scope>ZZAVC</scope><orcidid>https://orcid.org/0000-0003-3999-8747</orcidid></search><sort><creationdate>20241212</creationdate><title>BAY 81-8973 Demonstrates Long-Term Safety and Efficacy in Children With Severe Haemophilia A: Results From the LEOPOLD Kids Extension Study</title><author>Ljung, Rolf ; Chan, Anthony K C ; Ahuja, Sanjay P ; Mancuso, Maria Elisa ; Marquez, Jose Francisco Cabre ; Volk, Florian ; Blanchette, Victor ; Kerlin, Bryce A ; Trakymiene, Sonata Saulyte ; Glosli, Heidi ; Kenet, Gili</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p245t-e2bab62035d0c22f317c938df0e0878520e6e45ff3396d440f666b2548b015e83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Clinical Medicine</topic><topic>Hematologi</topic><topic>Hematology</topic><topic>Klinisk medicin</topic><topic>Medical and Health Sciences</topic><topic>Medicin och hälsovetenskap</topic><topic>Pediatrics</topic><topic>Pediatrik</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ljung, Rolf</creatorcontrib><creatorcontrib>Chan, Anthony K C</creatorcontrib><creatorcontrib>Ahuja, Sanjay P</creatorcontrib><creatorcontrib>Mancuso, Maria Elisa</creatorcontrib><creatorcontrib>Marquez, Jose Francisco Cabre</creatorcontrib><creatorcontrib>Volk, Florian</creatorcontrib><creatorcontrib>Blanchette, Victor</creatorcontrib><creatorcontrib>Kerlin, Bryce A</creatorcontrib><creatorcontrib>Trakymiene, Sonata Saulyte</creatorcontrib><creatorcontrib>Glosli, Heidi</creatorcontrib><creatorcontrib>Kenet, Gili</creatorcontrib><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SWEPUB Lunds universitet full text</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SWEPUB Lunds universitet</collection><collection>SwePub Articles full text</collection><jtitle>European journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ljung, Rolf</au><au>Chan, Anthony K C</au><au>Ahuja, Sanjay P</au><au>Mancuso, Maria Elisa</au><au>Marquez, Jose Francisco Cabre</au><au>Volk, Florian</au><au>Blanchette, Victor</au><au>Kerlin, Bryce A</au><au>Trakymiene, Sonata Saulyte</au><au>Glosli, Heidi</au><au>Kenet, Gili</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>BAY 81-8973 Demonstrates Long-Term Safety and Efficacy in Children With Severe Haemophilia A: Results From the LEOPOLD Kids Extension Study</atitle><jtitle>European journal of haematology</jtitle><addtitle>Eur J Haematol</addtitle><date>2024-12-12</date><risdate>2024</risdate><issn>1600-0609</issn><eissn>1600-0609</eissn><abstract>To report the long-term safety and efficacy of BAY 81-8973 in the LEOPOLD Kids extension phase. Patients received BAY 81-8973 (25-50 IU/kg) at least twice weekly. The primary endpoint was safety, assessed in all patients who entered the extension phase (n = 82). Efficacy endpoints were assessed in patients without high-titre inhibitors/immune tolerance induction (n = 67). Children (n = 82) received BAY 81-8973 for a median of 3.1 years per patient and a median of 405 exposure days per patient. Long-term BAY 81-8973 treatment was well tolerated, with no cases of de novo inhibitor development in the extension phase. Annualised bleeding rates (ABRs) within 48 h of prophylaxis were low for all bleeds (median [IQR], 0.7 [0-1.9]; mean, 1.4 [SD, 2.1]) and for joint bleeds (median [IQR], 0 [0-0.7]; mean, 0.5 [SD, 1.1]) (n = 67). Twenty-one of 67 patients (31.3%) had zero bleeds within 48 h of prophylaxis; the treatment response was 'good'/'excellent' in 87.9% of bleeds, and most bleeds resolved with ≤ 2 BAY 81-8973 infusions (83.5%). Long-term BAY 81-8973 treatment is well tolerated and maintains low ABRs for all bleeds and joint bleeds in children with severe haemophilia A. ClinicalTrials.gov identifier: NCT01311648.</abstract><cop>England</cop><pmid>39667975</pmid><doi>10.1111/ejh.14362</doi><orcidid>https://orcid.org/0000-0003-3999-8747</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1600-0609
ispartof European journal of haematology, 2024-12
issn 1600-0609
1600-0609
language eng
recordid cdi_proquest_miscellaneous_3146664467
source Wiley
subjects Clinical Medicine
Hematologi
Hematology
Klinisk medicin
Medical and Health Sciences
Medicin och hälsovetenskap
Pediatrics
Pediatrik
title BAY 81-8973 Demonstrates Long-Term Safety and Efficacy in Children With Severe Haemophilia A: Results From the LEOPOLD Kids Extension Study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T16%3A36%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=BAY%2081-8973%20Demonstrates%20Long-Term%20Safety%20and%20Efficacy%20in%20Children%20With%20Severe%20Haemophilia%20A:%20Results%20From%20the%20LEOPOLD%20Kids%20Extension%20Study&rft.jtitle=European%20journal%20of%20haematology&rft.au=Ljung,%20Rolf&rft.date=2024-12-12&rft.issn=1600-0609&rft.eissn=1600-0609&rft_id=info:doi/10.1111/ejh.14362&rft_dat=%3Cproquest_swepu%3E3146664467%3C/proquest_swepu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p245t-e2bab62035d0c22f317c938df0e0878520e6e45ff3396d440f666b2548b015e83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3146664467&rft_id=info:pmid/39667975&rfr_iscdi=true